Press releases – ASCELIA

All All press releases Regulatory press releases Financial reports

2021-12-16 | Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial

2021-12-01 | Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Regulatory

2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

Regulatory

2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration

2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed

Regulatory

2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Regulatory

2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level

Regulatory

2021-08-18 | Covid-19 extends recruitment period of SPARKLE study

2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA

2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance

Regulatory

2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch

Regulatory

2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Regulatory

2021-04-30 | Number of shares and votes in Ascelia Pharma AB

Regulatory

2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

Regulatory

2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB

Regulatory

2021-04-09 | Issue and repurchase of series C shares for share saving program

Regulatory

2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

Regulatory

2021-03-31 | Number of shares and votes in Ascelia Pharma AB